scholarly journals Real-World Treatment and Associated Healthcare Resource Use Among Migraine Patients in Germany

2021 ◽  
Author(s):  
Fraence Hardtstock
Keyword(s):  
Resource Use ◽  
Healthcare Resource ◽  
Indirect Costs ◽  
Prescription Data ◽  
Healthcare Resource Use ◽  
Early Discontinuation ◽  
Baseline Characteristics ◽  
Publicly Insured ◽  
Insured Patients ◽  
Cost Outcomes

Background: In order to evaluate unmet therapeutic need, this study sought to describe treatment patterns, as well as associated healthcare resource use (HCRU) and costs incurred by migraine patients in Germany. Methods: We conducted a retrospective analysis of a German claims dataset from 2013-2017, including over three million publicly-insured patients. Adult patients were included if they received at least one inpatient and/or two confirmed outpatient claims for headache/migraine from 2013-2016. Using prescription data from 2017, patients were separated into four main cohorts: those receiving prescriptions for (1) acute agents only, (2) prophylactic agents only, (3) both acute and prophylactic agents, and (4) neither acute nor prophylactic agents. Baseline characteristics were observed from 2013-2016; treatment and HCRU/cost outcomes were assessed in 2017. Results: In total, 199,283 patients were included in this analysis (mean age, 49.49 years; 73.04%, female) and 9,005 prophylactic therapy starters were identified. Overall, 43.47% of migraine patients did not receive acute or prophylactic medication in 2017, while 33.81% received only acute treatment, 9.45% received only prophylactic medication and 13.28% received both. Only 28.90% of patients initiating a prophylactic treatment were persistent after two years. HCRU was elevated for all groups, while direct costs ranged from €2,288-7,246 per year, and indirect costs ranged from €868-1,859. Conclusions: Despite high levels of HCRU, few migraine patients were treated with prophylactic agents, and those who did were at an elevated risk of early discontinuation. Ultimately, these findings indicate a resounding need for safe, timely, and efficacious use of prophylaxis among migraine patients.

scholarly journals Healthcare resource use and indirect costs associated with migraine in Italy: results from the My Migraine Voice survey

2021 ◽  
pp. 1-1
Author(s):  
Paolo Martelletti ◽  
Todd J. Schwedt ◽  
Pamela Vo ◽  
Daniela Ritrovato ◽  
Margaret C. Reilly ◽  
...  
Keyword(s):  
Resource Use ◽  
Healthcare Resource ◽  
Indirect Costs ◽  
Healthcare Resource Use

scholarly journals 1227. A Survey Study of Healthcare Resource Use, and Direct and Indirect Costs, Among Females with an Uncomplicated Urinary Tract Infection in the United States

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S702-S703
Author(s):  
Jeffrey Thompson ◽  
Alen Marijam ◽  
Fanny S Mitrani-Gold ◽  
Jonathon Wright ◽  
Ashish V Joshi
Keyword(s):  
Primary Care ◽  
Urinary Tract ◽  
Resource Use ◽  
Healthcare Resource ◽  
Work Productivity ◽  
Indirect Costs ◽  
Direct Costs ◽  
Urgent Care ◽  
Healthcare Resource Use ◽  
Direct And Indirect Costs

Abstract Background Uncomplicated urinary tract infections (uUTI) account for a large proportion of primary care antibiotic (AB) prescriptions. This study assessed uUTI-related healthcare resource use (HRU) and costs in US females with a self-reported uUTI. Methods We surveyed US females aged ≥ 18 years who participated in web-based surveys (fielded August 28–September 28, 2020 by Dynata, EMI, Lucid/Federated, and Kantar Profiles). Participants had a self-reported uUTI ≤ 60 days prior, and took ≥ 1 oral AB for their uUTI. Those reporting signs of complicated UTI were excluded. HRU was measured via self-reported primary care provider (PCP), specialist, urgent care, emergency room (ER) visits, and hospitalizations. Direct costs were calculated as sum of self-reported and HRU monetized with Medical Expenditure Panel Survey estimates. Indirect costs were calculated via Work Productivity and Impairment metrics monetized with Bureau of Labor Statistics estimates. Participants were stratified by number of oral ABs prescribed (1/2/3+) and therapy appropriateness (1 AB [1st line/2nd line]/multiple [any line] AB) for most recent uUTI. Multivariable regression modeling was used to compare strata; 1:1 propensity score matching assessed uUTI burden vs matched population (derived from the 2020 National Health and Wellness Survey [NHWS]). Results In total, 375 participants were eligible for this analysis. PCP visits (68.8%) were the most common HRU. Across participants, there were an average of 1.46 PCP, 0.31 obstetrician/gynecologist, 0.41 urgent care and 0.08 ER visits, and 0.01 hospitalizations for most recent uUTI (Table 1). Total mean uUTI-related direct and indirect costs were &1289 and &515, respectively (Table 1). Adjusted mean total direct costs were significantly higher (Table 2) for participants in the ‘2 AB’ cohort vs the ‘1 AB’ cohort (&2090 vs &776, p < 0.0001), and for the ‘multiple AB’ vs ‘1 AB, 1st line’ cohorts (&1642 vs &875, p=0.002). Participants in the uUTI cohort reported worse absenteeism (+15.3%), presenteeism (+46.5%), overall work impairment (+52.4%), and impact on daily activities (+50.7%) vs NHWS cohort (p < 0.0001, Table 3). Table 1. Overall mean uUTI-related healthcare resource use, direct, and indirect cost data Table 2. Estimated uUTI-related direct costs stratified by (A) number of AB and (B) appropriateness of AB therapy used to treat last uUTI Table 3. Mean Work Productivity and Activity Impairment data for uUTI and NHWS cohorts Conclusion Inadequate treatment response, evident by multiple AB use, was associated with an increase in uUTI-related costs, including productivity loss. Disclosures Jeffrey Thompson, PhD, Kantar Health (Employee, Employee of Kantar Health, which received funding from GlaxoSmithKline plc. to conduct this study) Alen Marijam, MSc, GlaxoSmithKline plc. (Employee, Shareholder) Fanny S. Mitrani-Gold, MPH, GlaxoSmithKline plc. (Employee, Shareholder) Jonathon Wright, BSc, Kantar Health (Employee, Employee of Kantar Health, which received funding from GlaxoSmithKline plc. to conduct this study) Ashish V. Joshi, PhD, GlaxoSmithKline plc. (Employee, Shareholder)

scholarly journals Predictors of poor health and functional recovery following road trauma: protocol of a British Columbian inception cohort study

BMJ Open ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. e049623
Author(s):  
Leona K Shum ◽  
Herbert Chan ◽  
Shannon Erdelyi ◽  
Lulu X Pei ◽  
Jeffrey R Brubacher
Keyword(s):  
Resource Use ◽  
Healthcare Resource ◽  
Healthcare Providers ◽  
Healthcare Resource Use ◽  
Physical And Mental Health ◽  
Inception Cohort ◽  
Policy Makers ◽  
Productivity Costs ◽  
Poor Outcome ◽  
Lost Productivity

IntroductionRoad trauma (RT) is a major public health problem affecting physical and mental health, and may result in prolonged absenteeism from work or study. It is important for healthcare providers to know which RT survivors are at risk of a poor outcome, and policy-makers should know the associated costs. Unfortunately, outcome after RT is poorly understood, especially for RT survivors who are treated and released from an emergency department (ED) without the need for hospital admission. Currently, there is almost no research on risk factors for a poor outcome among RT survivors. This study will use current Canadian data to address these knowledge gaps.Methods and analysisWe will follow an inception cohort of 1500 RT survivors (16 years and older) who visited a participating ED within 24 hours of the accident. Baseline interviews determine pre-existing health and functional status, and other potential risk factors for a poor outcome. Follow-up interviews at 2, 4, 6, and 12 months (key stages of recovery) use standardised health-related quality of life tools to determine physical and mental health outcome, functional recovery, and healthcare resource use and lost productivity costs.Ethics and disseminationThe Road Trauma Outcome Study is approved by our institutional Research Ethics Board. This study aims to provide healthcare providers with knowledge on how quickly RT survivors recover from their injuries and who may be more likely to have a poor outcome. We anticipate that this information will be used to improve management of all road users following RT. Healthcare resource use and lost productivity costs will be collected to provide a better cost estimate of the effects of RT. This information can be used by policy-makers to make informed decisions on RT prevention programmes.

scholarly journals Direct Costs And Healthcare Resource Use Associated With Advanced Melanoma In Portugal

2015 ◽  
Vol 18 (7) ◽  
pp. A466
Author(s):  
F Lopes ◽  
MJ Passos ◽  
A Raimundo ◽  
PA Laires
Keyword(s):  
Resource Use ◽  
Healthcare Resource ◽  
Direct Costs ◽  
Advanced Melanoma ◽  
Healthcare Resource Use
Sign in / Sign up

Export Citation Format

Share Document